<DOC>
	<DOCNO>NCT00695305</DOCNO>
	<brief_summary>A study patient atherosclerosis assess safety , effect PK rilapladib vs. placebo 12 week dose .</brief_summary>
	<brief_title>An Imaging Study Patients With Atherosclerosis Taking Rilapladib Placebo 12 Weeks</brief_title>
	<detailed_description>Study LP2105521 randomize , double-blind , placebo-controlled , parallel-group study examine safety , tolerability , effect rilapladib plasma Lp-PLA2 activity , plaque inflammation , PAF ( feasible ) . Subjects receive placebo rilapladib daily 12 week . The study conduct subject establish atherosclerosis .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Capable give write informed consent able understand comply protocol requirement , instruction protocolstated restriction . Male female , age 50 80 year inclusive , screen . Females must nonchildbearing potential Body weight ≥ 50 kg BMI within range 1935 kg/m2 Documented atherosclerotic vascular disease ( e.g . prior MI , prior revascularization , peripheral arterial disease , carotid disease , cerebrovascular disease ) clinically stable least 6 month If diabetic , well control diabetes , define purpose study HbA1c ≤8 % FPG ≤200 mg/dL Evidence plaque inflammation [ carotid artery ascend aorta plaque inflammation define tissue background ratio ( TBR ) ≥ 1.6 ] On stable dose statin 3 month prior screen evidence statin intolerance Recent ( i.e. , &lt; 6 month Screening Visit ) CV event define STelevation MI nonSTelevation MI , confirm cardiac enzyme elevation ECG change , coronary revascularization ( PCI CABG ) , stroke etiology , resuscitate sudden death , prior carotid surgery stenting procedure Evidence clinical instability abnormal clinical laboratory finding prior randomization , opinion Investigator , make subject unsuitable study . Exposure substantial radiation within past 12 month Planned cardiac surgery ( e.g. , CABG , valve repair replacement , aneurysmectomy ) , PCI major noncardiac surgery within study period Current inadequately control hypertension ( blood pressure ≥160 mmHg systolic ≥100 mmHg diastolic ) stable dose antihypertensive medication Diabetics take injectable insulin screen Serum triglyceride &gt; 400 mg/dL , LDLc &gt; 130 mg/dL Recent ( &lt; 1 month ) ongoing acute infection . History chronic inflammatory disease Recently receive ( &lt; 1 month ) currently receive oral injectable corticosteroid , regular use nasal , inhaled topical corticosteroid . Subjects commence , likely commence regular treatment oral , nonsteroidal antiinflammatory drug ( NSAIDs ) screen study completion Currently receive oral injectable potent CYP3A4 inhibitor ( ) History chronic viral hepatitis chronic hepatic disorder ; ALT AST &gt; 1.5 x ULN , alkaline phosphatase total bilirubin &gt; 1.5 x ULN laboratory reference range Screen Renal impairment serum creatinine &gt; 2.0 mg/dl history kidney transplant status post nephrectomy . History myopathy inflammatory muscle disease , elevate total CPK screen History severe heart failure define NYHA class III IV know severe leave ventricular dysfunction ( ejection fraction &lt; 30 % ) regardless symptomatic status History adult asthma ( reactive airway disease ) manifest bronchospasm past 6 month , currently take regular antiasthmatic medication ( ) History anaphylaxis , anaphylactoid ( resemble anaphylaxis ) reaction severe allergic response History malignancy within past 2 year . A history glaucoma finding baseline eye exam Current lifethreatening condition vascular disease may prevent subject complete study QTc interval ≥450msec screen ≥480 msec subject bundle branch block History drug abuse within past 6 month Previous exposure rilapladib . Contraindication MRI scan Use investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication Any subject Investigator deems unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>rilapladib ,</keyword>
	<keyword>Lp-PLA2 ,</keyword>
	<keyword>atherosclerosis</keyword>
	<keyword>SB-659032 ,</keyword>
	<keyword>FDG-PET ,</keyword>
</DOC>